sellWeak
Schayowitz Adam sold $358k of ZYME
EVP, Head of R&D at Zymeworks Inc.. 13,832 shares at an average of $25.85, traded Oct 9, 2026, filed Oct 9, 2026.
Warning score
25Value
$358k
13,832 shares
Holdings after
23,205
-37% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0002127119-26-000006, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Oct 9, 2026 | MOption exercise Common Stock | +37,037 | $0.00 | $0 | 37,037 | 28 h ago |
| Oct 9, 2026 | SOpen-market sale Common Stock | -13,832 | $25.85 | $358k | 23,205 | 28 h ago |
| Oct 9, 2026 | MOption exercise Restricted Stock Unitderivative | -37,037 | $0.00 | $0 | 74,074 | 28 h ago |
Related signals
Other insiders at Zymeworks Inc. and this insider’s other filings.
| Score | Side | Company | Insider | Value | Shares | Filed |
|---|---|---|---|---|---|---|
| 35Weak | buy | ZYME Zymeworks Inc. | EcoR1 Capital, LLC director, owner | $1.9M | 130,309 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.